Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

Core Viewpoint - Spero Therapeutics reported a quarterly loss of $0.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, marking an earnings surprise of -18.52% [1] Financial Performance - The company posted revenues of $13.47 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 41.44%, and down from $25.47 million in the same quarter last year [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $9 million, and for the current fiscal year, it is -$1.38 on revenues of $51.5 million [7] Stock Performance - Spero Therapeutics shares have declined approximately 10.9% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook [8]